Abstract
Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.
Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.
Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).
Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.
Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.
Original language | English |
---|---|
Article number | 5463451 |
Number of pages | 6 |
Journal | Multiple Sclerosis International |
Volume | 2020 |
DOIs | |
Publication status | Published - 2020 |
Fingerprint
Dive into the research topics of 'Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis'. Together they form a unique fingerprint.
View full fingerprint
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
Daniels, K., van der Nat, P. B., Frequin, S. T. F. M., van der Wees, P. J., Biesma, D. H., Hoogervorst, E. L. J. (2020). Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. Multiple Sclerosis International, 2020, Article 5463451. https://doi.org/10.1155/2020/5463451
Daniels, K ; van der Nat, P B ; Frequin, S T F M et al. / Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. In: Multiple Sclerosis International. 2020 ; Vol. 2020.
@article{f687cebb4ebb4069a719488f54706404,
title = "Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis",
abstract = "Background: Recently, ocrelizumab (Ocrevus{\textregistered}) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.",
author = "K Daniels and {van der Nat}, {P B} and Frequin, {S T F M} and {van der Wees}, {P J} and Biesma, {D H} and Hoogervorst, {E L J} and {van de Garde}, {E M W}",
note = "Copyright {\textcopyright} 2020 K. Daniels et al.",
year = "2020",
doi = "10.1155/2020/5463451",
language = "English",
volume = "2020",
journal = "Multiple Sclerosis International",
issn = "2090-2654",
publisher = "Hindawi Publishing Corporation",
}
Daniels, K, van der Nat, PB, Frequin, STFM, van der Wees, PJ, Biesma, DH, Hoogervorst, ELJ 2020, 'Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis', Multiple Sclerosis International, vol. 2020, 5463451. https://doi.org/10.1155/2020/5463451
Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. / Daniels, K; van der Nat, P B; Frequin, S T F M et al.
In: Multiple Sclerosis International, Vol. 2020, 5463451, 2020.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
AU - Daniels, K
AU - van der Nat, P B
AU - Frequin, S T F M
AU - van der Wees, P J
AU - Biesma, D H
AU - Hoogervorst, E L J
AU - van de Garde, E M W
N1 - Copyright © 2020 K. Daniels et al.
PY - 2020
Y1 - 2020
N2 - Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.
AB - Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.
U2 - 10.1155/2020/5463451
DO - 10.1155/2020/5463451
M3 - Article
C2 - 32607256
SN - 2090-2654
VL - 2020
JO - Multiple Sclerosis International
JF - Multiple Sclerosis International
M1 - 5463451
ER -
Daniels K, van der Nat PB, Frequin STFM, van der Wees PJ, Biesma DH, Hoogervorst ELJ et al. Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. Multiple Sclerosis International. 2020;2020:5463451. doi: 10.1155/2020/5463451